Harvey Philip, Curiel-Cid Rosie, Kallestrup Peter, Mueller Annalee, Rivera-Molina Andrea, Czaja Sara, Crocco Elizabeth, Loewenstein David
Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, United States, 1 3052434094.
i-Function, Inc, Miami, FL, United States.
JMIR Ment Health. 2025 Feb 19;12:e64716. doi: 10.2196/64716.
The early detection of mild cognitive impairment is crucial for providing treatment before further decline. Cognitive challenge tests such as the Loewenstein-Acevedo Scales for Semantic Interference and Learning (LASSI-L) can identify individuals at highest risk for cognitive deterioration. Performance on elements of the LASSI-L, particularly proactive interference, correlate with the presence of critical Alzheimer disease biomarkers. However, in-person paper tests require skilled testers and are not practical in many community settings or for large-scale screening in prevention.
This study reports on the development and initial validation of a self-administered computerized version of the Loewenstein-Acevedo Scales for Semantic Interference (LASSI), the digital LASSI (LASSI-D). A self-administered digital version, with an artificial intelligence-generated avatar assistant, was the migrated assessment.
Cloud-based software was developed, using voice recognition technology, for English and Spanish versions of the LASSI-D. Participants were assessed with either the LASSI-L or LASSI-D first, in a sequential assessment study. Participants with amnestic mild cognitive impairment (aMCI; n=54) or normal cognition (NC; n=58) were also tested with traditional measures such as the Alzheimer Disease Assessment Scale-Cognition. We examined group differences in performance across the legacy and digital versions of the LASSI, as well as correlations between LASSI performance and other measures across the versions.
Differences on recall and intrusion variables between aMCI and NC samples on both versions were all statistically significant (all P<.001), with at least medium effect sizes (d>0.68). There were no statistically significant performance differences in these variables between legacy and digital administration in either sample (all P<.13). There were no language differences in any variables (P>.10), and correlations between LASSI variables and other cognitive variables were statistically significant (all P<.01). The most predictive legacy variables, proactive interference and failure to recover from proactive interference, were identical across legacy and migrated versions within groups and were identical to results of previous studies with the legacy LASSI-L. Classification accuracy was 88% for NC and 78% for aMCI participants.
The results for the digital migration of the LASSI-D were highly convergent with the legacy LASSI-L. Across all indices of similarity, including sensitivity, criterion validity, classification accuracy, and performance, the versions converged across languages. Future studies will present additional validation data, including correlations with blood-based Alzheimer disease biomarkers and alternative forms. The current data provide convincing evidence of the use of a fully self-administered digitally migrated cognitive challenge test.
轻度认知障碍的早期检测对于在病情进一步恶化之前提供治疗至关重要。认知挑战测试,如用于语义干扰和学习的洛温斯坦 - 阿塞维多量表(LASSI-L),可以识别出认知能力恶化风险最高的个体。LASSI-L各部分的表现,特别是主动干扰,与关键的阿尔茨海默病生物标志物的存在相关。然而,纸质的现场测试需要熟练的测试人员,并且在许多社区环境中不实用,也不适用于大规模的预防筛查。
本研究报告了用于语义干扰的洛温斯坦 - 阿塞维多量表(LASSI)的自我管理计算机化版本——数字LASSI(LASSI-D)的开发和初步验证情况。带有人工智能生成的虚拟助手的自我管理数字版本是迁移评估。
使用语音识别技术开发了基于云的软件,用于LASSI-D的英语和西班牙语版本。在一项顺序评估研究中,参与者首先接受LASSI-L或LASSI-D评估。患有遗忘型轻度认知障碍(aMCI;n = 54)或认知正常(NC;n = 58)的参与者还接受了诸如阿尔茨海默病评估量表 - 认知等传统测量。我们检查了LASSI传统版本和数字版本在表现上的组间差异,以及LASSI表现与各版本其他测量之间的相关性。
两个版本的aMCI和NC样本在回忆和侵入变量上的差异均具有统计学意义(所有P <.001),效应量至少为中等(d > 0.68)。在任何一个样本中,传统管理和数字管理在这些变量上均无统计学意义的表现差异(所有P <.13)。任何变量均无语言差异(P >.10),并且LASSI变量与其他认知变量之间的相关性具有统计学意义(所有P <.01)。预测性最强的传统变量,即主动干扰和无法从主动干扰中恢复,在组内的传统版本和迁移版本中是相同的,并且与之前使用传统LASSI-L的研究结果相同。NC参与者的分类准确率为88%,aMCI参与者为78%。
LASSI-D的数字迁移结果与传统LASSI-L高度一致。在所有相似性指标上,包括敏感性、效标效度、分类准确率和表现,各版本在不同语言间是一致的。未来的研究将提供更多的验证数据,包括与基于血液的阿尔茨海默病生物标志物的相关性以及替代形式。当前数据为使用完全自我管理的数字迁移认知挑战测试提供了令人信服的证据。